Early Markers of Sensorineural Hearing Loss After Platinum-Based Chemotherapy
This study underscores the need for audiometric monitoring, including EHFs as well as ototoxicity grading systems. Furthermore, our results confirm that EFR magnitude may represent a valuable noninvasive marker of CS caused by platinum-based chemotherapy. A decline in EFR magnitude was observed before the onset of subjective complaints or significant audiometric threshold changes. These findings support the inclusion of objective measures, such as the EFR, in monitoring protocols to enhance early detection of ototoxicity.
Authors
- Ingeborg Dhooge (ORCID: https://orcid.org/0000-0002-5915-1079)
- Sarah Verhulst (ORCID: https://orcid.org/0000-0002-6498-7719)
- Hannah Keppler (ORCID: https://orcid.org/0000-0002-8684-9448)
- Sylvie Rottey (ORCID: https://orcid.org/0000-0003-2060-3725)
- Eline Naert (ORCID: https://orcid.org/0000-0002-1508-7263)
- Sarineh Keshishzadeh (ORCID: https://orcid.org/0000-0003-0081-8243)
- Heleen Van Der Biest (ORCID: https://orcid.org/0000-0001-7174-3950)
Institutions
- HOGENT University of Applied Sciences and Arts (BE)
- Ghent University Hospital (BE)
- Ghent University (BE)
Publication Details
- Journal
- Ear and Hearing
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1097/aud.0000000000001714
- Primary Topic
- Hearing, Cochlea, Tinnitus, Genetics
- Type
- article
- Field-Weighted Citation Impact
- 0.00